Outcomes of Percutaneous Tracheostomy for Patients with SARS-CoV-2 Respiratory Failure

• DOI: 10.1101/2021.02.23.21252231
• Publication Date: 2021-02-25T10:57:06Z
• Authors: Jason Arnold; Catherine A. Gao; Elizabeth Malsin; Kristy Todd; A. Christine Argento; Michael Cuttica; John M. Coleman; Richard G. Wunderink; Sean B. Smith
• Keywords: 2019-20 coronavirus outbreak

ABSTRACT Background SARS-CoV-2 can cause severe respiratory failure leading to prolonged mechanical ventilation. Data are just emerging about the practice and outcomes of tracheostomy in these patients. We reviewed our experience with tracheostomies for at tertiary-care, urban teaching hospital. Methods demographics, comorbidities, timing ventilation, tracheostomy, ICU hospital lengths-of-stay (LOS) patients who received tracheostomies. Early was considered <14 days Medians interquartile ranges (IQR) were calculated compared Wilcoxon rank sum, Spearman correlation, Kruskal-Wallis, regression modeling. Results From March 2020 January 2021, center had 370 intubated SARS-CoV-2, 59 (16%) percutaneous bedside tracheostomy. Median time from intubation 19 (IQR 17 – 24) days. Demographics comorbidities similar between early late but associated shorter LOS a trend towards To date, 34 (58%) have been decannulated, (29%) before discharge; median decannulation 24 19-38) Decannulated younger (56 vs 69 years), analysis, pneumothorax lower rates (OR 0.05, 95CI 0.01 0.37). No providers developed symptoms or tested positive SARS-CoV-2. Conclusions Tracheostomy is safe reasonable procedure failure. feel that enhances care since appears duration critical care, appear high survivors.